Valuation: Genmab A/S

Market Cap 138B 20.99B 18.52B 17.52B 15.89B 29.79B 2,014B 30.09B 210B 81.02B 1,028B 78.8B 77.09B 3,309B P/E 2026 *
28.9x
P/E 2027 * 20.8x
Enterprise Value 158B 23.9B 21.09B 19.96B 18.1B 33.93B 2,293B 34.26B 239B 92.26B 1,171B 89.74B 87.79B 3,769B EV / Sales 2026 *
5.43x
EV / Sales 2027 * 4.44x
Free-Float
94.3%
Yield 2026 *
-
Yield 2027 * -
1 day+0.65%
1 week+1.67%
Current month+9.19%
1 month+7.47%
3 months+34.83%
6 months+37.71%
Current year+14.31%
1 week 2,256
Extreme 2256
2,340
1 month 2,066
Extreme 2066
2,340
Current year 1,512
Extreme 1512
2,340
1 year 1,512
Extreme 1512
2,340
3 years 1,157
Extreme 1157
2,532
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 2010-05-31
Director of Finance/CFO 48 2020-02-29
Chief Tech/Sci/R&D Officer - 2024-08-15
Director TitleAgeSince
Director/Board Member 75 2003-10-31
Director/Board Member 58 2014-12-31
Director/Board Member 75 2014-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
12/1/25 Exercice

Director

189 0.0003%
12/1/25 Exercice

Director

189 0.0003%
12/1/25 Exercice

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+0.65%+1.67%+26.47%-7.62% 20.92B
-0.70%-4.28%+52.62%+86.42% 71.81B
+0.45%-0.82%+38.81%+84.19% 60.06B
+2.34%+3.60%+33.48%+23.06% 27.93B
-1.73%-4.30%-18.37%+357.94% 25.7B
-0.51%-2.28%+0.48%-9.27% 24.89B
+3.46%+3.02%+158.90%+337.81% 15.04B
+0.48%+0.86%+44.56%+168.42% 14.46B
+0.34%-1.74%-7.67%+503.82% 13.87B
+5.88%-4.26%-22.54%+776.47% 12.35B
Average +0.38%-1.67%+30.68%+232.13% 28.7B
Weighted average by Cap. +0.17%-1.95%+34.10%+156.11%

Financials

2026 *2027 *
Net sales 29.02B 4.4B 3.88B 3.67B 3.33B 6.24B 422B 6.31B 44.06B 16.98B 216B 16.52B 16.16B 694B 33.67B 5.1B 4.5B 4.26B 3.86B 7.25B 490B 7.32B 51.12B 19.7B 250B 19.17B 18.75B 805B
Net income 4.98B 755M 666M 630M 571M 1.07B 72.42B 1.08B 7.56B 2.91B 36.98B 2.83B 2.77B 119B 7.1B 1.08B 950M 899M 815M 1.53B 103B 1.54B 10.78B 4.16B 52.75B 4.04B 3.95B 170B
Net Debt 19.22B 2.91B 2.57B 2.43B 2.21B 4.14B 280B 4.18B 29.18B 11.25B 143B 10.94B 10.7B 459B 11.06B 1.68B 1.48B 1.4B 1.27B 2.38B 161B 2.4B 16.79B 6.47B 82.12B 6.29B 6.16B 264B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
26-09-29 DKK 2,317.00 +0.65% 142,718
26-09-28 DKK 2,302.00 +1.10% 122,997
26-09-25 DKK 2,277.00 +0.40% 99,355
26-09-24 DKK 2,268.00 -1.05% 79,887
26-09-23 DKK 2,292.00 +0.57% 118,274
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
2,317.00DKK
Average target price
2,453.79DKK
Spread / Average Target
+5.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock